Andreas Argyrides
Stock Analyst at Oppenheimer
(4.34)
# 365
Out of 5,134 analysts
119
Total ratings
52.43%
Success rate
18.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EVMN Evommune | Initiates: Outperform | $42 | $31.20 | +34.62% | 1 | Jan 22, 2026 | |
| DYN Dyne Therapeutics | Upgrades: Outperform | $11 → $40 | $15.28 | +161.78% | 5 | Dec 10, 2025 | |
| SVRA Savara | Maintains: Outperform | $8 → $9 | $5.73 | +57.07% | 2 | Nov 14, 2025 | |
| KROS Keros Therapeutics | Reiterates: Outperform | $23 → $27 | $16.52 | +63.44% | 9 | Nov 12, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $54.22 | +112.12% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.03 | +593.07% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $10.36 | +180.06% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.40 | +8,191.46% | 2 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $482.42 | +19.19% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $5.54 | +170.76% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $20 | $5.04 | +296.83% | 2 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $61 | $36.92 | +65.22% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $3.88 | +80.41% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $0.85 | +253.23% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $33.84 | -61.58% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $1.28 | +212.50% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $11.48 | +683.97% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $1.45 | +520.69% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $223.41 | -18.98% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $17.52 | +493.61% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.15 | +318.60% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.38 | +102.56% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $28.77 | +0.80% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.04 | +161.19% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $17.88 | +1,152.80% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.74 | +150.66% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.92 | +663.11% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.37 | +2,602.70% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $59.95 | +16.76% | 6 | Aug 1, 2023 |
Evommune
Jan 22, 2026
Initiates: Outperform
Price Target: $42
Current: $31.20
Upside: +34.62%
Dyne Therapeutics
Dec 10, 2025
Upgrades: Outperform
Price Target: $11 → $40
Current: $15.28
Upside: +161.78%
Savara
Nov 14, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $5.73
Upside: +57.07%
Keros Therapeutics
Nov 12, 2025
Reiterates: Outperform
Price Target: $23 → $27
Current: $16.52
Upside: +63.44%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $54.22
Upside: +112.12%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.03
Upside: +593.07%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $10.36
Upside: +180.06%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.40
Upside: +8,191.46%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $482.42
Upside: +19.19%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $5.54
Upside: +170.76%
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $5.04
Upside: +296.83%
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $36.92
Upside: +65.22%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $3.88
Upside: +80.41%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $0.85
Upside: +253.23%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $33.84
Upside: -61.58%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $1.28
Upside: +212.50%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $11.48
Upside: +683.97%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.45
Upside: +520.69%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $223.41
Upside: -18.98%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $17.52
Upside: +493.61%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.15
Upside: +318.60%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.38
Upside: +102.56%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $28.77
Upside: +0.80%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.04
Upside: +161.19%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $17.88
Upside: +1,152.80%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.74
Upside: +150.66%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.92
Upside: +663.11%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.37
Upside: +2,602.70%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $59.95
Upside: +16.76%